Anesthetic cardioprotection in clinical practice from proof-of-concept to clinical applications

Current Pharmaceutical Design

Volumn 20, Issue 36, 2014, Pages 5706-5726

  Zaugg, Michael ^a   Lucchinetti, Eliana ^b   Behmanesh, Saeid ^c   Clanachan, Alexander S ^b  

^a MAZANKOWSKI ALBERTA HEART INSTITUTE   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

Anesthetics; Cardiac surgery; Cardioprotection; Noncardiac surgery; Postconditioning; Preconditioning; Propofol; Remifentanil; Sevoflurane

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; GLITAZONE DERIVATIVE; INHALATION ANESTHETIC AGENT; OPIATE; PROPOFOL; SEVOFLURANE; SULFONYLUREA DERIVATIVE; NARCOTIC ANALGESIC AGENT;

ARTICLE; CLINICAL PRACTICE; CORONARY ARTERY BYPASS GRAFT; HEART PROTECTION; HEART SURGERY; HUMAN; ISCHEMIC PRECONDITIONING; MYOCARDIAL DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSLATIONAL RESEARCH; ANIMAL; DRUG INTERACTION; HEART INFARCTION PREVENTION; ISCHEMIC POSTCONDITIONING; MYOCARDIAL ISCHEMIA; POSTOPERATIVE COMPLICATIONS; PRACTICE GUIDELINE; PROCEDURES; RISK FACTOR;

ANALGESICS, OPIOID; ANESTHETICS, INHALATION; ANIMALS; CORONARY ARTERY BYPASS; DRUG INTERACTIONS; HUMANS; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL ISCHEMIA; POSTOPERATIVE COMPLICATIONS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 84925762435     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140204120829     Document Type: Article

References (147)

1. Weiser TG, Regenbogen SE, Thompson KD, et al. An estimation of the global volume of surgery: a modelling strategy based on available data. Lancet 2008; 372: 139-44.
2. Zaugg M, Schaub MC and Foex P. Myocardial injury and its prevention in the perioperative setting. Br J Anaesth 2004; 93: 21-33.
3. Tuman KJ, McCarthy RJ, Spiess BD, et al. Does choice of anesthetic agent significantly affect outcome after coronary artery surgery? Anesthesiology 1989; 70: 189-98.
4. Eagle KA, Brundage BH, Chaitman BR, et al. Guidelines for perioperative cardiovascular evaluation for noncardiac surgery. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Committee on Perioperative Cardiovascular Evaluation for Noncardiac Surgery. Circulation 1996; 93: 1278-317.
5. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 2007; 116: 1971-96.
6. Hillis LD, Smith PK, Anderson JL, et al. Special Articles: 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Anesth Analg 2011; 114: 11-45.
7. Zaugg M, Ed. Perioperative Organ Protection. Best Practice & Research Clinical Anesthesiology 2008; 22: Oxfordshire, UK: Elsevier.
8. Kersten JR, Schmeling TJ, Pagel PS, et al. Isoflurane mimics ischemic preconditioning via activation of K(ATP) channels: reduction of myocardial infarct size with an acute memory phase. Anesthesiology 1997; 87: 361-70.
9. Schultz JE, Hsu AK and Gross GJ. Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamidesensitive mechanism in the rat heart. Circ Res 1996; 78: 1100-4.
10. Fukuda S, Kaga S, Sasaki H, et al. Angiogenic signal triggered by ischemic stress induces myocardial repair in rat during chronic infarction. J Mol Cell Cardiol 2004; 36: 547-59.
11. Burwell LS, Nadtochiy SM and Brookes PS. Cardioprotection by metabolic shut-down and gradual wake-up. J Mol Cell Cardiol 2009; 46: 804-10.
12. Sedlic F, Pravdic D, Ljubkovic M, et al. Differences in production of reactive oxygen species and mitochondrial uncoupling as events in the preconditioning signaling cascade between desflurane and sevoflurane. Anesth Analg 2009; 109: 405-11.
13. Zaugg M, Lucchinetti E, Spahn DR, et al. Volatile anesthetics mimic cardiac preconditioning by priming the activation of mitochondrial K(ATP) channels via multiple signaling pathways. Anesthesiology 2002; 97: 4-14.
14. da Silva R, Grampp T, Pasch T, et al. Differential activation of mitogen-activated protein kinases in ischemic and anesthetic preconditioning. Anesthesiology 2004; 100: 59-69.
15. Feng, J Lucchinetti E, Enkavi G, et al. Tyrosine phosphorylation by Src within the cavity of the adenine nucleotide translocase 1 regulates ADP/ATP exchange in mitochondria. Am J Physiol Cell Physiol 2010; 298: C740-8.
16. Obal D, Weber NC, Zacharowski K, et al. Role of protein kinase C-epsilon (PKCepsilon) in isoflurane-induced cardioprotection. Br J Anaesth 2005; 94: 166-73.
17. Uecker M, Da Silva R, Grampp T, et al. Translocation of protein kinase C isoforms to subcellular targets in ischemic and anesthetic preconditioning. Anesthesiology 2003; 99: 138-47.
18. Sergeev P, da Silva R, Lucchinetti E, et al. Trigger-dependent gene expression profiles in cardiac preconditioning: evidence for distinct genetic programs in ischemic and anesthetic preconditioning. Anesthesiology 2004; 100: 474-88.
19. Tanaka K, Ludwig LM, Krolikowski JG, et al. Isoflurane produces delayed preconditioning against myocardial ischemia and reperfusion injury: role of cyclooxygenase-2. Anesthesiology 2004; 100: 525-31.
20. Tonkovic-Capin M, Gross GJ, Bosnjak ZJ, et al. Delayed cardioprotection by isoflurane: role of K(ATP) channels. Am J Physiol Heart Circ Physiol 2002; 283: H61-8.
21. Tanaka K, Ludwig LM, Kersten JR, et al. Mechanisms of cardioprotection by volatile anesthetics. Anesthesiology 2004; 100: 707-21.
22. Zaugg M, Lucchinetti E, Garcia C, et al. Anaesthetics and cardiac preconditioning. Part II. Clinical implications. Br J Anaesth 2003; 91: 566-76.
23. Zaugg M, Lucchinetti E, Uecker M, et al. Anaesthetics and cardiac preconditioning. Part I. Signalling and cytoprotective mechanisms. Br J Anaesth 2003; 91: 551-65.
24. Zaugg M and Schaub MC. Signaling and cellular mechanisms in cardiac protection by ischemic and pharmacological preconditioning. J Muscle Res Cell Motil 2003; 24: 219-49.
25. De Hert SG, Van der Linden PJ, Cromheecke S, et al. Cardioprotective properties of sevoflurane in patients undergoing coronary surgery with cardiopulmonary bypass are related to the modalities of its administration. Anesthesiology 2004; 101: 299-310.
26. Lucchinetti E, Hofer C, Bestmann L, et al. Gene regulatory control of myocardial energy metabolism predicts postoperative cardiac function in patients undergoing off-pump coronary artery bypass graft surgery: inhalational versus intravenous anesthetics. Anesthesiology 2007; 106: 444-57.
27. Murry CE, Jennings RB and Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-36.
28. Bein B, Renner J, Caliebe D, et al. The effects of interrupted or continuous administration of sevoflurane on preconditioning before cardio-pulmonary bypass in coronary artery surgery: comparison with continuous propofol. Anaesthesia 2008; 63: 1046-55.
29. Frassdorf J, Borowski A, Ebel D, et al. Impact of preconditioning protocol on anesthetic-induced cardioprotection in patients having coronary artery bypass surgery. J Thorac Cardiovasc Surg 2009; 137: 1436-42, 42 e1-2.
30. Riess ML, Kevin LG, Camara AK, et al. Dual exposure to sevoflurane improves anesthetic preconditioning in intact hearts. Anesthesiology 2004; 100: 569-74.
31. Bolli R. Preconditioning: a paradigm shift in the biology of myocardial ischemia. Am J Physiol Heart Circ Physiol 2007; 292: H19-27.
32. Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003; 285: H579-88.
33. Feng J, Lucchinetti E, Ahuja P, et al. Isoflurane postconditioning prevents opening of the mitochondrial permeability transition pore through inhibition of glycogen synthase kinase 3beta. Anesthesiology 2005; 103: 987-95.
34. Preckel B, Schlack W, Comfere T, et al. Effects of enflurane, isoflurane, sevoflurane and desflurane on reperfusion injury after regional myocardial ischaemia in the rabbit heart in vivo. Br J Anaesth 1998; 81: 905-12.
35. Lucchinetti E, da Silva R, Pasch T, et al. Anaesthetic preconditioning but not postconditioning prevents early activation of the deleterious cardiac remodelling programme: evidence of opposing genomic responses in cardioprotection by pre-and postconditioning. Br J Anaesth 2005; 95: 140-52.
36. Kuzuya T, Hoshida S, Yamashita N, et al. Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res 1993; 72: 1293-9.
37. Marber MS, Latchman DS, Walker JM, et al. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation 1993; 88: 1264-72.
38. Bravo C, Kudej RK, Yuan C, et al. Metabolomic analysis of two different models of delayed preconditioning. J Mol Cell Cardiol 2013; 55: 19-26.
39. Lucchinetti E, Aguirre J, Feng J, et al. Molecular evidence of late preconditioning after sevoflurane inhalation in healthy volunteers. Anesth Analg 2007; 105: 629-40.
40. Kaeffer N, Richard V, Francois A, et al. Preconditioning prevents chronic reperfusion-induced coronary endothelial dysfunction in rats. Am J Physiol 1996; 271: H842-9.
41. Pearson, PJ, Schaff, HV and Vanhoutte, PM. Long-term impairment of endothelium-dependent relaxations to aggregating platelets after reperfusion injury in canine coronary arteries. Circulation 1990; 81: 1921-7.
42. Lucchinetti E, Zeisberger SM, Baruscotti I, et al. Stem cell-like human endothelial progenitors show enhanced colony-forming capacity after brief sevoflurane exposure: preconditioning of angiogenic cells by volatile anesthetics. Anesth Analg 2009; 109: 1117-26.
43. Lucchinetti E, Ambrosio S, Aguirre J, et al. Sevoflurane inhalation at sedative concentrations provides endothelial protection against ischemia-reperfusion injury in humans. Anesthesiology 2007; 106: 262-8.
44. Kloner RA, Shook T, Przyklenk K, et al. Previous angina alters inhospital outcome in TIMI 4. A clinical correlate to preconditioning? Circulation 1995; 91: 37-45.
45. Muller DW, Topol EJ, Califf RM, et al. Relationship between antecedent angina pectoris and short-term prognosis after thrombolytic therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Am Heart J 1990; 119: 224-31.
46. Ishihara M, Sato H, Tateishi H, et al. Implications of prodromal angina pectoris in anterior wall acute myocardial infarction: acute angiographic findings and long-term prognosis. J Am Coll Cardiol 1997; 30: 970-5.
47. De Hert S, Vlasselaers D, Barbe R, et al. A comparison of volatile and non volatile agents for cardioprotection during on-pump coronary surgery. Anaesthesia 2009; 64: 953-60.
48. Garcia C, Julier K, Bestmann L, et al. Preconditioning with sevoflurane decreases PECAM-1 expression and improves oneyear cardiovascular outcome in coronary artery bypass graft surgery. Br J Anaesth 2005; 94: 159-65.
49. Gross ER, Peart JN, Hsu AK, et al. Extending the cardioprotective window using a novel delta-opioid agonist fentanyl isothiocyanate via the PI3-kinase pathway. Am J Physiol Heart Circ Physiol 2005; 288: H2744-9.
50. Dana A, Baxter GF, Walker JM, et al. Prolonging the delayed phase of myocardial protection: repetitive adenosine A1 receptor activation maintains rabbit myocardium in a preconditioned state. J Am Coll Cardiol 1998; 31: 1142-9.
51. Luca MC, Liuni A, McLaughlin K, et al. Daily ischemic preconditioning provides protection from ischemia reperfusion induced endothelial dysfunction: a human study. J Am Heart Assoc 2013; 2013: e000075 doi: 10. 1161/JAHA. 112.
52. Hellstrom J, Owall A, Bergstrom J, et al. Cardiac outcome after sevoflurane versus propofol sedation following coronary bypass surgery: a pilot study. Acta Anaesthesiol Scand 2011; 55: 460-7.
53. Soro M, Gallego L, Silva V, et al. Cardioprotective effect of sevoflurane and propofol during anaesthesia and the postoperative period in coronary bypass graft surgery: a double-blind randomised study. Eur J Anaesthesiol 2011; 29: 561-9.
54. Zaugg M, Wang L, Zhang L, et al. Choice of anesthetic combination determines Ca2+ leak after ischemia-reperfusion injury in the working rat heart: favorable versus adverse combinations. Anesthesiology 2012; 116: 648-57.
55. Assad AR, Delou JM, Fonseca LM, et al. The role of KATP channels on propofol preconditioning in a cellular model of renal ischemia-reperfusion. Anesth Analg 2009; 109: 1486-92.
56. Javadov SA, Lim KH, Kerr PM, et al. Protection of hearts from reperfusion injury by propofol is associated with inhibition of the mitochondrial permeability transition. Cardiovasc Res 2000; 45: 360-9.
57. Xia Z, Godin DV and Ansley DM. Propofol enhances ischemic tolerance of middle-aged rat hearts: effects on 15-F(2t)-isoprostane formation and tissue antioxidant capacity. Cardiovasc Res 2003; 59: 113-21.
58. Ansley DM, Raedschelders K, Chen DD, et al. Rationale, design and baseline characteristics of the PRO-TECT II study: PROpofol CardioproTECTion for Type II diabetics: a randomized, controlled trial of high-dose propofol versus isoflurane preconditioning in patients undergoing on-pump coronary artery bypass graft surgery. Contemp Clin Trials 2009; 30: 380-5.
59. Wang L, Ko KW, Lucchinetti E, et al. Metabolic profiling of hearts exposed to sevoflurane and propofol reveals distinct regulation of fatty acid and glucose oxidation: CD36 and pyruvate dehydrogenase as key regulators in anesthetic-induced fuel shift. Anesthesiology 2010; 113: 541-51.
60. Perrault LP, Menasche P, Bel A, et al. Ischemic preconditioning in cardiac surgery: a word of caution. J Thorac Cardiovasc Surg 1996; 112: 1378-86.
61. da Silva R, Lucchinetti E, Pasch T, et al. Ischemic but not pharmacological preconditioning elicits a gene expression profile similar to unprotected myocardium. Physiol Genomics 2004; 20: 117-30.
62. Miki T, Miura T, Tanno M, et al. Interruption of signal transduction between G protein and PKC-epsilon underlies the impaired myocardial response to ischemic preconditioning in postinfarct remodeled hearts. Mol Cell Biochem 2003; 247: 185-93.
63. Lucchinetti E, Bestmann L, Feng J, et al. Remote ischemic preconditioning applied during isoflurane inhalation provides no benefit to the myocardium of patients undergoing on-pump coronary artery bypass graft surgery: lack of synergy or evidence of antagonism in cardioprotection? Anesthesiology 2012; 116: 296-310.
64. Iliodromitis EK, Kyrzopoulos S, Paraskevaidis IA, et al. Increased C reactive protein and cardiac enzyme levels after coronary stent implantation. Is there protection by remote ischaemic preconditioning? Heart 2006; 92: 1821-6.
65. Heusch G. Cardioprotection: chances and challenges of its translation to the clinic. Lancet 2013; 381: 166-75.
66. Karuppasamy P, Chaubey S, Dew T, et al. Remote intermittent ischemia before coronary artery bypass graft surgery: a strategy to reduce injury and inflammation? Basic Res Cardiol 2011; 106: 511-9.
67. Zaugg M, Lucchinetti E, Clanachan A, et al. Remote ischemic preconditioning is redundant in patients undergoing coronary artery bypass graft surgery who are already protected by volatile anesthetics. Circ Res 2012; 110: e42-3.
68. Belhomme D, Peynet J, Louzy M, et al. Evidence for preconditioning by isoflurane in coronary artery bypass graft surgery. Circulation 1999; 100: II340-4.
69. Pouzet B, Lecharny JB, Dehoux M, et al. Is there a place for preconditioning during cardiac operations in humans? Ann Thorac Surg 2002; 73: 843-8.
70. Julier K, da Silva R, Garcia C, et al. Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded, placebo-controlled, multicenter study. Anesthesiology 2003; 98: 1315-27.
71. Lorsomradee S, Cromheecke S and De Hert SG. Effects of sevoflurane on biomechanical markers of hepatic and renal dysfunction after coronary artery surgery. J Cardiothorac Vasc Anesth 2006; 20: 684-90.
72. De Hert SG, Cromheecke S, ten Broecke PW, et al. Effects of propofol, desflurane, and sevoflurane on recovery of myocardial function after coronary surgery in elderly high-risk patients. Anesthesiology 2003; 99: 314-23.
73. Cromheecke S, Pepermans V, Hendrickx E, et al. Cardioprotective properties of sevoflurane in patients undergoing aortic valve replacement with cardiopulmonary bypass. Anesth Analg 2006; 103: 289-96.
74. De Hert SG, Van der Linden PJ, Cromheecke S, et al. Choice of primary anesthetic regimen can influence intensive care unit length of stay after coronary surgery with cardiopulmonary bypass. Anesthesiology 2004; 101: 9-20.
75. Symons JA and Myles PS. Myocardial protection with volatile anaesthetic agents during coronary artery bypass surgery: a metaanalysis. Br J Anaesth 2006; 97: 127-36.
76. Yu CH and Beattie WS. The effects of volatile anesthetics on cardiac ischemic complications and mortality in CABG: a metaanalysis. Can J Anaesth 2006; 53: 906-18.
77. Landoni G, Biondi-Zoccai GG, Zangrillo A, et al. Desflurane and sevoflurane in cardiac surgery: a meta-analysis of randomized clinical trials. J Cardiothorac Vasc Anesth 2007; 21: 502-11.
78. Bignami E, Biondi-Zoccai G, Landoni G, et al. Volatile anesthetics reduce mortality in cardiac surgery. J Cardiothorac Vasc Anesth 2009; 23: 594-9.
79. Jakobsen CJ, Berg H, Hindsholm KB, et al. The influence of propofol versus sevoflurane anesthesia on outcome in 10, 535 cardiac surgical procedures. J Cardiothorac Vasc Anesth 2007; 21: 664-71.
80. Huang Z, Zhong X, Irwin MG, et al. Synergy of isoflurane preconditioning and propofol postconditioning reduces myocardial reperfusion injury in patients. Clin Sci (Lond) 2011; 121: 57-69.
81. Xia Z, Huang Z and Ansley DM. Large-dose propofol during cardiopulmonary bypass decreases biochemical markers of myocardial injury in coronary surgery patients: a comparison with isoflurane. Anesth Analg 2006; 103: 527-32.
82. Mangano DT, Siliciano D, Hollenberg M, et al. Postoperative myocardial ischemia. Therapeutic trials using intensive analgesia following surgery. The Study of Perioperative Ischemia (SPI) Research Group. Anesthesiology 1992; 76: 342-53.
83. Wong GT, Huang Z, Ji S, et al. Remifentanil reduces the release of biochemical markers of myocardial damage after coronary artery bypass surgery: a randomized trial. J Cardiothorac Vasc Anesth 2010; 24: 790-6.
84. Murphy GS, Szokol JW, Marymont JH, et al. Opioids and cardioprotection: the impact of morphine and fentanyl on recovery of ventricular function after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2006; 20: 493-502.
85. Bein B, Renner J, Caliebe D, et al. Sevoflurane but not propofol preserves myocardial function during minimally invasive direct coronary artery bypass surgery. Anesth Analg 2005; 100: 610-6, table of contents.
86. Kim TY, Kim DK, Yoon TG, et al. Myocardial injury in remifentanil-based anaesthesia for off-pump coronary artery bypass surgery: an equipotent dose of sevoflurane versus propofol. Anaesth Intensive Care 2011; 39: 418-25.
87. Law-Koune JD, Raynaud C, Liu N, et al. Sevoflurane-remifentanil versus propofol-remifentanil anesthesia at a similar bispectral level for off-pump coronary artery surgery: no evidence of reduced myocardial ischemia. J Cardiothorac Vasc Anesth 2006; 20: 484-92.
88. Zangrillo A, Testa V, Aldrovandi V, et al. Volatile agents for cardiac protection in noncardiac surgery: a randomized controlled study. J Cardiothorac Vasc Anesth 2011; 25: 902-7.
89. Lurati Buse GA, Schumacher P, Seeberger E, et al. Randomized comparison of sevoflurane versus propofol to reduce perioperative myocardial ischemia in patients undergoing noncardiac surgery. Circulation 2012; 126: 2696-704.
90. Zaugg M. Is protection by inhalation agents volatile? Controversies in cardioprotection. Br J Anaesth 2007; 99: 603-6.
91. Tani M, Suganuma Y, Hasegawa H, et al. Changes in ischemic tolerance and effects of ischemic preconditioning in middle-aged rat hearts. Circulation 1997; 95: 2559-66.
92. Mio Y, Bienengraeber MW, Marinovic J, et al. Age-related attenuation of isoflurane preconditioning in human atrial cardiomyocytes: roles for mitochondrial respiration and sarcolemmal adenosine triphosphate-sensitive potassium channel activity. Anesthesiology 2008; 108: 612-20.
93. Abete P, Ferrara N, Cacciatore F, et al. Angina-induced protection against myocardial infarction in adult and elderly patients: a loss of preconditioning mechanism in the aging heart? J Am Coll Cardiol 1997; 30: 947-54.
94. Ishihara M, Sato H, Tateishi H, et al. Beneficial effect of prodromal angina pectoris is lost in elderly patients with acute myocardial infarction. Am Heart J 2000; 139: 881-8.
95. Jimenez-Navarro M, Gomez-Doblas JJ, Alonso-Briales J, et al. Does angina the week before protect against first myocardial infarction in elderly patients? Am J Cardiol 2001; 87: 11-5.
96. Zhu J, Rebecchi MJ, Wang Q, et al. Chronic Tempol treatment restores pharmacological preconditioning in the senescent rat heart. Am J Physiol Heart Circ Physiol 2013; 304: H649-59.
97. Boengler K, Schulz R and Heusch G. Loss of cardioprotection with ageing. Cardiovasc Res 2009; 83: 247-61.
98. Kersten, JR Montgomery MW, Ghassemi T, et al. Diabetes and hyperglycemia impair activation of mitochondrial K(ATP) channels. Am J Physiol Heart Circ Physiol 2001; 280: H1744-50.
99. Szilvassy Z, Ferdinandy P, Szilvassy J, et al. The loss of pacinginduced preconditioning in atherosclerotic rabbits: role of hypercholesterolaemia. J Mol Cell Cardiol 1995; 27: 2559-69.
100. Goel, DP, Pierce GN. The role of the sodium-hydrogen exchanger in ischemia-reperfusion injury in diabetes. J Thrombosis Thrombolysis1999; 8: 45-51.
101. Meinert CL, Knatterud GL, Prout TE, et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970; 19: Suppl: 789-830.
102. Forlani S, Tomai F, De Paulis R, et al. Preoperative shift from glibenclamide to insulin is cardioprotective in diabetic patients undergoing coronary artery bypass surgery. J Cardiovasc Surg (Torino) 2004; 45: 117-22.
103. Nissen SE and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71.
104. Yue TI TL, Chen J, Bao W, et al. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferatoractivated receptor-gamma agonist rosiglitazone. Circulation 2001; 104: 2588-94.
105. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011; 34: 916-22.
106. Lou PH, Zhang L, Lucchinetti E, et al. Infarct-remodelled hearts with limited oxidative capacity boost fatty acid oxidation after conditioning against ischaemia/reperfusion injury. Cardiovasc Res 2012; 97: 251-61.
107. Ghosh S, Standen NB and Galinianes M. Failure to precondition pathological human myocardium. J Am Coll Cardiol 2001; 37: 711-8.
108. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352: 1081-91.
109. Feng J, Lucchinetti E, Fischer G, et al. Cardiac remodelling hinders activation of cyclooxygenase-2, diminishing protection by delayed pharmacological preconditioning: role of HIF1 alpha and CREB. Cardiovasc Res 2008; 78: 98-107.
110. Garcia Rodriguez LA and Gonzalez-Perez A. Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. BMC Med 2005; 3: 17.
111. Grosser T, Fries S and FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4-15.
112. Zaugg M and Schaub MC. Cellular mechanisms in sympathomodulation of the heart. Br J Anaesth 2004; 93: 34-52.
113. Zaugg M, Schulz C, Wacker J, et al. Sympatho-modulatory therapies in perioperative medicine. Br J Anaesth 2004; 93: 53-62.
114. Wikstrom BG, Ronquist G and Waldenstrom A. No further improvement of ischaemic myocardial metabolism by combining preconditioning with beta-blockade: an in vivo experimental study in the pig heart using a microdialysis technique. Acta Physiol Scand 1997; 159: 23-32.
115. Lange M, Smul TM, Blomeyer CA, et al. Role of the beta1-adrenergic pathway in anesthetic and ischemic preconditioning against myocardial infarction in the rabbit heart in vivo. Anesthesiology 2006; 105: 503-10.
116. Zaugg M and Schaub MC. Genetic modulation of adrenergic activity in the heart and vasculature: implications for perioperative medicine. Anesthesiology 2005; 102: 429-46.
117. Zaugg M, Schaub MC, Pasch T, et al. Modulation of betaadrenergic receptor subtype activities in perioperative medicine: mechanisms and sites of action. Br J Anaesth 2002; 88: 101-23.
118. Nette AF, Abraham G, Ungemach FR, et al. Interaction between simvastatin and metoprolol with respect to cardiac betaadrenoceptor density, catecholamine levels and perioperative catecholamine requirements in cardiac surgery patients. Naunyn Schmiedebergs Arch Pharmacol 2005; 372: 115-24.
119. Neubauer H, Gunesdogan B, Hanefeld C, et al. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function-a flow cytometry study. Eur Heart J 2003; 24: 1744-9.
120. Aitchison KA, Baxter GF, Awan MM, et al. Opposing effects on infarction of delta and kappa opioid receptor activation in the isolated rat heart: implications for ischemic preconditioning. Basic Res Cardiol 2000; 95: 1-10.
121. Carr CS and Yellon DM. Ischaemic preconditioning may abolish the protection afforded by ATP-sensitive potassium channel openers in isolated human atrial muscle. Basic Res Cardiol 1997; 92: 252-60.
122. Roscoe AK, Christensen JD and Lynch C, 3rd. Isoflurane, but not halothane, induces protection of human myocardium via adenosine A1 receptors and adenosine triphosphate-sensitive potassium channels. Anesthesiology 2000; 92: 1692-701.
123. Gepts E, Camu F, Cockshott ID, et al. Disposition of propofol administered as constant rate intravenous infusions in humans. Anesth Analg 1987; 66: 1256-63.
124. Ludwig LM, Patel HH, Gross GJ, et al. Morphine enhances pharmacological preconditioning by isoflurane: role of mitochondrial K(ATP) channels and opioid receptors. Anesthesiology 2003; 98: 705-11.
125. Guo Y, Flaherty MP, Wu WJ, et al. Genetic background, gender, age, body temperature, and arterial blood pH have a major impact on myocardial infarct size in the mouse and need to be carefully measured and/or taken into account: results of a comprehensive analysis of determinants of infarct size in 1, 074 mice. Basic Res Cardiol 2012; 107: 288.
126. Ghaderian SM, Akbarzadeh Najar R and Tabatabaei Panah AS. Tumor necrosis factor-alpha: investigation of gene polymorphism and regulation of TACE-TNF-alpha system in patients with acute myocardial infarction. Mol Biol Rep 2011; 38: 4971-7.
127. Gueant-Rodriguez RM, Juilliere Y, Battaglia-Hsu SF, et al. Association of IL1B polymorphism with left ventricular systolic dysfunction: a relation with the release of interleukin-1beta in stress condition. Pharmacogenet Genomics 2011; 21: 579-86.
128. Otte C, Wust S, Zhao S, et al. Glucocorticoid receptor gene, lowgrade inflammation, and heart failure: the Heart and Soul study. J Clin Endocrinol Metab 2010; 95: 2885-91.
129. Tang Z, Diamond MA, Chen JM, et al. Polymorphisms in adenosine receptor genes are associated with infarct size in patients with ischemic cardiomyopathy. Clin Pharmacol Ther 2007; 82: 435-40.
130. Kersten JR. A recipe for perioperative cardioprotection: what matters most? The ingredients or the chef? Circulation 2012; 126: 2671-3.
131. Slogoff S and Keats AS. Randomized trial of primary anesthetic agents on outcome of coronary artery bypass operations. Anesthesiology 1989; 70: 179-88.
132. Tomai F, De Paulis R, Penta de Peppo A, et al. Beneficial impact of isoflurane during coronary bypass surgery on troponin I release. G Ital Cardiol 1999; 29: 1007-14.
133. Penta de Peppo A, Polisca P, Tomai F, et al. Recovery of LV contractility in man is enhanced by preischemic administration of enflurane. Ann Thorac Surg 1999; 68: 112-8.
134. Haroun-Bizri S, Khoury SS, Chehab IR, et al. Does isoflurane optimize myocardial protection during cardiopulmonary bypass? J Cardiothorac Vasc Anesth 2001; 15: 418-21.
135. De Hert SG, ten Broecke PW, Mertens E, et al. Sevoflurane but not propofol preserves myocardial function in coronary surgery patients. Anesthesiology 2002; 97: 42-9.
136. El Azab SR, Rosseel PM, De Lange JJ, et al. Effect of sevoflurane on the ex vivo secretion of TNF-alpha during and after coronary artery bypass surgery. Eur J Anaesthesiol 2003; 20: 380-4.
137. Lu CC, Ho ST, Wang JJ, et al. Minimal low-flow isoflurane-based anesthesia benefits patients undergoing coronary revascularization via preventing hyperglycemia and maintaining metabolic homeostasis. Acta Anaesthesiol Sin 2003; 41: 165-72.
138. Parker FC, Story DA, Poustie S, et al. Time to tracheal extubation after coronary artery surgery with isoflurane, sevoflurane, or targetcontrolled propofol anesthesia: a prospective, randomized, controlled trial. J Cardiothorac Vasc Anesth 2004; 18: 613-9.
139. Nader ND, Li CM, Khadra WZ, et al. Anesthetic myocardial protection with sevoflurane. J Cardiothorac Vasc Anesth 2004; 18: 269-74.
140. Fellahi JL, Gue X, Philippe E, et al. Isoflurane may not influence postoperative cardiac troponin I release and clinical outcome in adult cardiac surgery. Eur J Anaesthesiol 2004; 21: 688-93.
141. Kawamura T, Kadosaki M, Nara N, et al. Effects of sevoflurane on cytokine balance in patients undergoing coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2006; 20: 503-8.
142. Lee MC, Chen CH, Kuo MC, et al. Isoflurane preconditioninginduced cardio-protection in patients undergoing coronary artery bypass grafting. Eur J Anaesthesiol 2006; 23: 841-7.
143. Piriou V, Mantz J, Goldfarb G, et al. Sevoflurane preconditioning at 1 MAC only provides limited protection in patients undergoing coronary artery bypass surgery: a randomized bi-centre trial. Br J Anaesth 2007; 99: 624-31.
144. Conzen PF, Fischer S, Detter C, et al. Sevoflurane provides greater protection of the myocardium than propofol in patients undergoing off-pump coronary artery bypass surgery. Anesthesiology 2003; 99: 826-33.
145. Guarracino F, Landoni G, Tritapepe L, et al. Myocardial damage prevented by volatile anesthetics: a multicenter randomized controlled study. J Cardiothorac Vasc Anesth 2006; 20: 477-83.
146. Ballester M, Llorens J, Garcia-de-la-Asuncion J, et al. Myocardial oxidative stress protection by sevoflurane vs. propofol: a randomised controlled study in patients undergoing off-pump coronary artery bypass graft surgery. Eur J Anaesthesiol 2011; 28: 874-81.
147. Tempe DK, Dutta D, Garg M, et al. Myocardial protection with isoflurane during off-pump coronary artery bypass grafting: a randomized trial. J Cardiothorac Vasc Anesth 2010; 25: 59-65.